Ero sivun ”Etanersepti” versioiden välillä
Siirry navigaatioon
Siirry hakuun
| [katsottu versio] | [katsottu versio] |
Poistettu sisältö Lisätty sisältö
Ei muokkausyhteenvetoa |
|||
| Rivi 1: | Rivi 1: | ||
{{Roskaa||A2}} |
|||
'''Enbrel''' on lääke joka hoitaa autoimmuunisairauksia TNF-infektoituneilla. is a drug that treats autoimmune diseases by interfering with [[tumor necrosis factor]] (TNF; a soluble inflammatory cytokine) by acting as a [[TNF inhibitor]]. Pfizer describes in a [[U.S. Securities and Exchange Commission|SEC]] filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.<ref>[http://www.sec.gov/Archives/edgar/data/78003/000119312511048877/dex13.htm Sales reached $3b in 2010]</ref> |
'''Enbrel''' on lääke joka hoitaa autoimmuunisairauksia TNF-infektoituneilla. is a drug that treats autoimmune diseases by interfering with [[tumor necrosis factor]] (TNF; a soluble inflammatory cytokine) by acting as a [[TNF inhibitor]]. Pfizer describes in a [[U.S. Securities and Exchange Commission|SEC]] filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.<ref>[http://www.sec.gov/Archives/edgar/data/78003/000119312511048877/dex13.htm Sales reached $3b in 2010]</ref> |
||
Versio 15. syyskuuta 2012 kello 01.31
Enbrel on lääke joka hoitaa autoimmuunisairauksia TNF-infektoituneilla. is a drug that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. Pfizer describes in a SEC filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.[1]
Indikaatiot hoitoon
USA:ssa FDA on lisensoinut Enbrel:n käytön seuraaviin hoitoihin :
- Lievästä vakavvaan Nivelreuma (RA) ( 1998 marraskuu)
- Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) (1999)
- Psoriatic Arthritis (2002)
- Selkärankareuma (AS) (July 2003)[2]
- Moderate to Severe Plaque Psoriasis (April 2004)
Aiheesta muualla